Page 28 - நானோ தொழில்நுட்பம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Researchers use SARS-CoV-2 to bioengineer universal vaccine platform A team of scientists from the United States has recently developed a bioengineered bacteriophage T4 nanoparticle structure using CRISPR technology that can be used as a universal platform to produce vaccines. They used severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a model to develop the platform. The study is currently available on the Design of T4-SARS-CoV-2 nanovaccine by CRISPR engineering. Engineered DNAs corresponding to various components of SARS-CoV-2 virion are incorporated into bacteriophage T4 genome. Each DNA was introduced into E. coli as a donor plasmid (a), recombined into injected phage genome through CRISPR-targeted genome editing (b). Different combinations of CoV-2 inserts were then generated by simple phage infections and identifying the recombinant phages in the progeny (c). For example, recombinant phage containing CoV-2 insert #1 (dark blue) can be used to infect CRISPR E.

United statesSanchari sinha duttaSupplementary videoWhile socDesign multiplexNano technologySars cov 2Corona virusE coliGenome editingSevere acute respiratorySevere acute respiratory syndromeஒன்றுபட்டது மாநிலங்களில்சஞ்சரி சீன்ஹா தத்தாதுணை காணொளிபோது சமூக